Haematologica HAEMATOL/2015/135103 Version 3

Hyperhomocysteinemia and high doses of nilotinib favour cardio-vascular events in chronic phase Chronic Myelogenous Leukemia patients

Gaëlle Fossard, Emilie Blond, Marie Balsat, Stéphane Morisset, Stephane Giraudier, Martine Escoffre-Barbe, Hélène Labussière-Wallet, Maël Heiblig, Arthur Bert, Madeleine Etienne, Jocelyne Drai, Mohamad Sobh, Isabelle Redonnet-Vernhet, Jean-Christophe Lega, François-Xavier Mahon, Gabriel Etienne, and Franck Emmanuel Nicolini

Disclosures: Gaëlle Fossard, Emilie Blond, Marie Balsat, Stéphane Morisset, Maël Heiblig, Arthur Bert, Madeleine Etienne, Jocelyne Drai, Mohamad Sobh, Isabelle Vernhet, have nothing to disclose. Stéphane Giraudier has given some lectures for Novartis and Bristol Myers Squibb Martine Escoffre-Barbe has nothing to disclose. Helene Labussière-Wallet has been a board entity for Bristol Myers Squibb. Jean-Christophe Lega has nothing to disclose. François-Xavier Mahon is a consultant for Bristol Myers Squibb, Pfizer and Novartis and has given some lectures for these companies. He has received research grants from Novartis and Bristol Myers Squibb, Gabriel Etienne is a consultant for Novartis and Bristol Myers Squibb, Ariad, and Novartis and Pfizer. He has received research grants from Novartis and Bristol Myers Squibb, Franck Emmanuel Nicolini is a consultant for Bristol Myers Squibb, Ariad, and Novartis and has given some lectures for these companies. He has received a research grant from Novartis.

Contributions: GF has implemented some data, interpreted the data, seen some patients and wrote the paper. EB, JD, IR-V performed and supervised the biochemical assessments. MB, SG, ME-B, HL-W, MH, AB, JCL, FXM, GE and FE-N treated patients and collected clinical data. ME implemented the database. SM performed statistical analyses. MS performed editorial assistance. GE and FEN co-designed the study and set-it up. FEN collected the data, supervised their implementation, and wrote the manuscript with GF. All contributors have reviewed this letter and given their agreement on the last version of this manuscript for publication.